US OptionsDetailed Quotes
IBB241122C130000
- 7.40
- +1.70+29.82%
15min DelayClose Nov 22 15:59 ET
7.40High7.40Low
7.40Open5.70Pre Close1 Volume2 Open Interest130.00Strike Price740.00Turnover1607.70%IV-0.41%PremiumNov 22, 2024Expiry Date7.96Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9496Delta0.0202Gamma16.82Leverage Ratio-130.5182Theta0.0000Rho15.98Eff Leverage0.0003Vega
iShares Biotechnology ETF Stock Discussion
Sign in to post a comment
More and more friends around me are buying $Invesco QQQ Trust (QQQ.US)$. A friend has always lamented that they should have bought it sooner, not counting dividends. The coupon price alone has gone up quite a bit, and they don't know what the heck it would be to buy a-shares. ![]()
What is the overall pattern of the US stock bull market over the past ten years?![]()
People often ask me about my experience in investing in US stocks. I...
What is the overall pattern of the US stock bull market over the past ten years?
People often ask me about my experience in investing in US stocks. I...
+1
31
1
Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...
+1
15
3
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
$Immuneering (IMRX.US)$ $SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$ $S&P 500 Index (.SPX.US)$ $BioAtla (BCAB.US)$ $Gilead Sciences (GILD.US)$ $Affimed NV (AFMD.US)$ $Instil Bio (TIL.US)$ $Nkarta (NKTX.US)$
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
10
1
$iShares Biotechnology ETF (IBB.US)$
Buy this ETF before the biotechnology boom will come next time
Buy this ETF before the biotechnology boom will come next time
$SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer (PFE.US)$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences (GILD.US)$ 's $4.3 b...
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer (PFE.US)$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences (GILD.US)$ 's $4.3 b...
6
$SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$
Observations from $VINC (-60% AH):
1- When companies tout "strong safety profile", often means efficacy is a big fat zero
2- Phrases like "dose dependent clinical activity" set the bar low
3- "Promising" doesn't necessarily refer to SP
Stay skeptical, my friends.
Observations from $VINC (-60% AH):
1- When companies tout "strong safety profile", often means efficacy is a big fat zero
2- Phrases like "dose dependent clinical activity" set the bar low
3- "Promising" doesn't necessarily refer to SP
Stay skeptical, my friends.
3
$SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$
Mike on biotech's correlation with interest rates:
"Biotech is essentially a call option on $iShares 20+ Year Treasury Bond ETF (TLT.US)$
Biotech bulls need inflation and rates to move lower for resumption of a real bull market.
XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower.
Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...
Mike on biotech's correlation with interest rates:
"Biotech is essentially a call option on $iShares 20+ Year Treasury Bond ETF (TLT.US)$
Biotech bulls need inflation and rates to move lower for resumption of a real bull market.
XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower.
Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...
5
Since the beginning of this year, $NVIDIA (NVDA.US)$ has been leading a group of semiconductor and AI stocks to further rise in response to the breakthroughs in AI technology and a booming industry outlook. However, an increasing number of investors have started to fret over the potential risks behind the high valuations of AI stocks and are scouting for alternative investment opportunities. Some of them have shifted their focus to biotech stocks...
61
3
$SPDR S&P Biotech ETF (XBI.US)$ $iShares Biotechnology ETF (IBB.US)$
Big Pharma’s patent cliff issue getting mainstream media attention,
Top 20 biopharma have $180 bil in sales at risk from patent expirations by 2028 according to EY,
But that estimate could prove low compared to…👇
Bloomberg Intelligence business estimates 170 drugs w/ close to $400 bil in est global sales could lose patent excl by start of next decade,
Big Pharma wants to avoid stagnant rev g...
Big Pharma’s patent cliff issue getting mainstream media attention,
Top 20 biopharma have $180 bil in sales at risk from patent expirations by 2028 according to EY,
But that estimate could prove low compared to…👇
Bloomberg Intelligence business estimates 170 drugs w/ close to $400 bil in est global sales could lose patent excl by start of next decade,
Big Pharma wants to avoid stagnant rev g...
+3
4
No comment yet
Ishah : Well, due to the fact that a man who are married will increased their income by 4 + folds, I would say that the woman has a right to claim her husband's wealth. Even Jeff Bezos, he accredited his success to his exwife. A billionaire status is not a one man project. All the billionaires are or were married when the work was put in to make all their money. Do you know of any single men who have been single all their lives who have billions of dollars? I can't recall. Similar to a wife who is your mother, Elon Musk and Maye Musk, they operate as husband and wife... now that marriage brings the downfall of companies and legacies.